Patents Assigned to Suzhou Longbiotech Pharmaceuticals Co., Ltd.
  • Heterocyclic compound as JAK inhibitor, and salts and therapeutic use thereof
    Patent number: 11414413
    Abstract: Disclosed are a heterocyclic derivative as a JAK inhibitor, and salts thereof, wherein the definitions of (II), (III) and R are described in detail in the specification. In addition, also disclosed are a medicine including the compound and salts thereof as an active ingredient, and the use thereof in the preparation of a medicine for treating JAK-related target diseases, such as immune system diseases, rheumatoid arthritis and tumors.
    Type: Grant
    Filed: July 25, 2017
    Date of Patent: August 16, 2022
    Assignee: Suzhou Longbiotech Pharmaceuticals Co., Ltd.
    Inventors: Hengying Yang, Sheng Kuang, Shiwei Li, Kuiwang Wu, Shuxin Li
  • Compound as selective JAK inhibitor, and salt and therapeutic use thereof
    Patent number: 11279699
    Abstract: Disclosed are a compound as a selective JAK inhibitor, and an isomer, a solvate or a pharmaceutically acceptable salt thereof, wherein: the definitions of (A), R, R1 and n are described in detail in the specification. In addition, also disclosed are a medicament including the compound and salts thereof as an active ingredient, and the use thereof in the preparation of a medicament for treating JAK-related target diseases, such as immune system diseases, rheumatoid arthritis and tumors.
    Type: Grant
    Filed: July 25, 2017
    Date of Patent: March 22, 2022
    Assignee: Suzhou Longbiotech Pharmaceuticals Co., Ltd.
    Inventors: Hengying Yang, Sheng Kuang, Shiwei Li, Kuiwang Wu, Shuxin Li